Vir Biotechnology, Inc. Stock Price, News & Analysis

Vir Biotechnology, Inc. (Nasdaq: VIR) announced the acceptance of three abstracts showcasing its hepatitis B clinical program for presentation at the AASLD The Liver Meeting, scheduled for November 12-15, 2021. Among these, a key oral presentation will detail Phase 2 study results for VIR-2218, an investigational siRNA targeting chronic hepatitis B. Two posters will focus on VIR-3434, a monoclonal antibody aimed at inhibiting HBV, as well as patient experiences with chronic HBV. These presentations underscore the company's commitment to advancing innovative treatments against hepatitis B.

Vir Biotechnology announced that Chief Medical Officer Phil Pang, M.D., Ph.D., will present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Conference on October 13 at 9:30 a.m. PT / 12:30 p.m. ET. A live webcast will be available via the Investors section of the Vir website and will be archived for 30 days post-event.

Vir focuses on using advanced technologies to combat serious infectious diseases, with ongoing projects targeting COVID-19, hepatitis B, influenza A, and HIV.

Vir Biotechnology, Inc. (Nasdaq: VIR) announced that its Chief Medical Officer, Phil Pang, M.D., Ph.D., will present at the Guggenheim 2^nd Annual Vaccine & Infectious Disease Day Conference on October 6, 2021, at 11:30 a.m. PT / 2:30 p.m. ET. A live webcast of the presentation will be available on the company's Investors page and archived for 30 days. Vir focuses on immunological solutions for infectious diseases, with a pipeline targeting COVID-19, hepatitis B, influenza A, and HIV.

Vir Biotechnology, Inc. (Nasdaq: VIR) announced that CEO George Scangos, Ph.D., will engage in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 9:30 a.m. PT / 12:30 p.m. ET. Investors can access a live webcast from the Investors section of the Vir website, which will also be archived for 30 days after the event. The company emphasizes the importance of monitoring its website for material information and updates on its development pipeline, which focuses on serious infectious diseases.

Vir Biotechnology announces that CFO Howard Horn will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 4:00 a.m. PT / 7:00 a.m. ET. The presentation will be available via live webcast on the company's website and archived for 30 days.

Vir focuses on leveraging immunologic insights and technology to combat infectious diseases, with a development pipeline targeting COVID-19, hepatitis B, influenza A, and HIV.

Vir Biotechnology has received the first marketing authorization for its monoclonal antibody, sotrovimab, in Australia. This approval from the Australian Therapeutic Goods Administration allows sotrovimab, branded as Xevudy®, to be used in adults and adolescents with COVID-19 at risk of severe outcomes. Sotrovimab has already been authorized for emergency use in the U.S. and received favorable opinions in other regions. Vir is collaborating with GlaxoSmithKline to distribute sotrovimab, which shows efficacy against current SARS-CoV-2 variants.

Vir Biotechnology, Inc. (Nasdaq: VIR) announced robust second-quarter 2021 results, achieving total revenues of $177.1 million, a significant increase from $67.0 million YoY. Key developments include the emergency use authorization of monoclonal antibody sotrovimab for high-risk COVID-19 patients and positive data showing its efficacy against prevalent variants. The company also advanced its hepatitis B portfolio, initiating multiple clinical trials. Notably, net income reached $61.8 million, or $0.48 per share, reversing a loss from the previous year.

Vir Biotechnology and GlaxoSmithKline have entered a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, a monoclonal antibody treatment for COVID-19. This agreement aims to provide rapid access to sotrovimab for high-risk patients in participating EU Member States. Sotrovimab has shown a 79% reduction in hospitalizations/deaths in clinical trials. The companies are also pursuing ongoing evaluations to ensure effectiveness against new virus variants, emphasizing the urgent need for effective treatments amid the ongoing pandemic.

Vir Biotechnology (Nasdaq: VIR) announced it will provide a corporate update along with its financial results for Q2 2021 on August 5, 2021. The press release will be accessible after market close on their website. Vir focuses on combining immunologic insights with advanced technologies to combat serious infectious diseases, with a development pipeline that includes candidates targeting COVID-19, hepatitis B, influenza A, and HIV.